Disruptive behavior disorder comprises a group of disorders including oppositional defiant disorder, conduct disorder, and intermittent explosive disorder. It usually affects young people below 18 years of age. Children/teenagers suffering from this disorder are unable to regulate her/his emotions and behaviors, act defiant, and are in conflict with other peers in surrounding thereby facing low quality of life at home, school, or both.

Various causes of DBD include child abuse or neglect, a traumatic life experience, such as sexual abuse or violence, and a family history of DBDs. DBDs can be treated with variety of option, initiated with psychological therapy. Under psychological therapy, counselling and guidance is provided either to parent or child alone, or family together, to improve response to incidence of DBDs. Medication treatment is preferred either in combination with psychological treatment or started when psychological therapy proves to be insufficient.

Request A Sample Copy: http://bit.ly/2Tz4sHz

Disruptive Behavior Disorder Medication Market - Market Dynamics

Major factors responsible for growth of the disruptive behavior disorder medication market are rising burden of the disruptive behavior disorders worldwide, increasing awareness amongst parent about this disorder, and improvement of psychotic and medication treatment.

According to a study published in the journal BMJ Open (Matthew D Burkey et al) in 2015, oppositional defiant disorder (ODD) and conduct disorder (CD) had an estimated worldwide prevalence of 3.3% and 3.2%, respectively. World Health Organization in its 2016 factsheet stated that globally, 7.4 % of disability-adjusted life years (DALYs) are caused by disorders in mental and behavioral disorders category.

Disruptive Behavior Disorder Medication Market - Competitive Landscape

Key players present in the disruptive behavior disorder medication market are Promius Pharma LLC, Shire PLC, Johnson and Johnson, Mylan N.V., Novartis AG, Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Lupin Ltd., and Eli Lilly and Company.

Click To Read More On Disruptive Behavior Disorder (DBD) Medication Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]